Cited by 42Medical Imaging Techniques and ApplicationsLung Cancer Diagnosis and TreatmentRadiology practices and education

Evidence-based management of incidental focal uptake of fluorodeoxyglucose on PET-CT

Open access
Pencharz, Deborah, Nathan, Malavika, Wagner, Thomas L·2018·The British Journal of Radiology

Abstract

Focal incidental uptake, with or without CT abnormalities, is a common finding on fluorodeoxyglucose PET/CT and evidence-based management for this type of uptake is lacking. This article reviews the evidence on focal incidental uptake including the incidence of malignancy, differential diagnosis and imaging criteria which can be used to further characterize it. The article focusses on PET rather than CT criteria. The strength of the evidence base is highly variable ranging from systematic reviews and meta-analyses to a virtual absence of evidence. Caution needs to be used when using standardized uptake values (SUVs) reported in other studies due to interpatient and institution observed variation in SUVs. There is sufficient evidence to permit specific suggestions on how to interpret the foci and recommend further management in the: pituitary (investigate when SUVmax >4.1), thyroid (investigate all), breast (investigate all), lung parenchyma (if focus of fluorodeoxyglucose without a CT nodule, no further investigations), colon (investigate all foci with SUVmax >5.9, urgently if SUVmax >11.4), adrenals (criteria depend on if patient has cancer) and prostate gland (investigate in males aged >50 years or >40 years if peripheral uptake or patient has other risk factors). There is some evidence to guide further management for the parotid gland, naso-orophaynx, oesophagus, pancreas, uterus and ovaries. There is insufficient evidence to guide management for the liver, spleen, kidneys, gallbladder, testis and bone, for these organs patient characteristics and other guidelines will likely be of more use in determining further management.

Integrity signals

Registry

Crossref · 10.1259/bjr.20170774

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Despite PBMAH being benign, limited studies using FDG uptake demonstrated uptake similar to malignant tumors.

    “Despite PBMAH being a benign disease limited studies using FDG uptake demonstrated an uptake similar to that seen in malignant tumors (326).”

    From Adrenal incidentaloma (2020) · cites this paper as [326]

Cites

Flagged first, then by citations

2 of the 92 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Pencharz, D., Nathan, M., & Wagner, T. L.
Affiliations
  • Brighton and Sussex University Hospitals NHS Trust (GB)
  • Royal Free London NHS Foundation Trust (GB)
Venue
The British Journal of Radiology
Published
2018-01-31
Volume
91
Issue
1084
Pages
20170774-20170774
ISSN
  • 0007-1285 (ISSN-L)
  • 1748-880X
OpenAlex
W2775337940
Cited by
42
References
92
Citations by year
2026: 4 · 2025: 2 · 2024: 7 · 2023: 6 · 2022: 5 · 2021: 9 · 2020: 4 · 2019: 3 · 2018: 1 · 2015: 1
FWCI
1.68
Type
journal article
Language
en
Open access
Locations
  • British Journal of Radiology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiology practices and education
Keywords
18F-FDG PET/CT, standardized uptake value, SUVmax, malignancy incidence, differential diagnosis, pituitary gland, thyroid gland, breast, lung parenchyma, colon, adrenal gland, prostate, parotid gland, nasopharynx, esophagus, pancreas, uterus, ovary, cancer risk stratification, follow-up management
MeSH terms
Positron Emission Tomography Computed Tomography, Diagnosis, Differential, Humans, Tissue Distribution, Radiopharmaceuticals, Evidence-Based Medicine, Fluorodeoxyglucose F18, Incidental Findings

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review